title: Evaluating the efficacy of therapeutic HIV vaccines through analytical treatment interruptions.
abstract: BACKGROUND
  The development of an effective therapeutic HIV vaccine that induces immunologic control of viral replication, thereby eliminating or reducing the need for antiretroviral therapy (ART), would be of great value. Besides the obvious challenges of developing a therapeutic vaccine that would generate effective, sustained anti-HIV immunity in infected individuals is the issue of how to best assess the efficacy of vaccine candidates.
  
  
  CONCLUSIONS
  This review discusses the various outcome measures assessed in therapeutic HIV vaccine clinical trials involving individuals receiving suppressive ART, with a particular focus on the role of analytical treatment interruption (ATI) as a way to assess the virologic control induced by an immunotherapy. This strategy is critical given that there are otherwise no readily available measures to determine the ability of a vaccine-induced immune response to effectively control HIV replication. The various outcome measures that have been used to assess vaccine efficacy in published therapeutic HIV vaccine clinical trials will also be discussed. Outcome measures have included the kinetics of viral rebound, the new viral set point and changes in the size of the viral reservoir. Clinically relevant outcomes such as the CD4 decline, the time to resume therapy or the time to meet the criterion to resume therapy, the proportion of participants who resume therapy and/or the development of clinical symptoms such as acute retroviral syndrome are also measures of vaccine efficacy.
  
  
  CONCLUSIONS
  Given the lack of consistency between therapeutic HIV vaccine trials in how efficacy is assessed, comparing vaccines has been difficult. It would, therefore, be beneficial to determine the most clinically relevant measure for use in future studies. Other recommendations for future clinical trials also include studying compartments in addition to blood and replacing ATIs with single-copy assays in situations in which the use of an ATI is not ideal.
authors.affiliation: Ottawa Hospital Research Institute, Ottawa, ON, Canada.
authors.forename: Gina M
authors.initials: GM
authors.lastname: Graziani
authors.affiliation: Ottawa Hospital Research Institute, Ottawa, ON, Canada.|Division of Infectious Disease, The Ottawa Hospital, Ottawa, ON, Canada; jangel@ohri.ca.
authors.forename: Jonathan B
authors.initials: JB
authors.lastname: Angel
mesh_terms: D016915:AIDS Vaccines / Q000627:therapeutic use*; D000328:Adult; D002986:Clinical Trials as Topic; D005260:Female; D015658:HIV Infections / Q000628:therapy* / Q000821:virology; D006801:Humans; D008297:Male; D014779:Virus Replication
chemical_list: D016915:AIDS Vaccines
keywords: AIDS; HIV; analytical treatment interruption(s); clinical trials; outcome measure; therapeutic vaccine; vaccine efficacy; viral reservoir